Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Glad to be here.

<< Previous

Bullboard Posts

Next >>

Comment by Reidraideron Dec 09, 2020 4:28pm

348 Views

Post# 32070269

RE:RE:RE:RE:Glad to be here.

in the US dollar mmed trades on an over the counter market mmed.f and in canadian funds it trades on the neo mmed.n , hope the uplist to nasdaq is soon then to the tsx to follow so alot of stocks trade on more than one market in different currency

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing